Market revenue in 2023 | USD 203.3 million |
Market revenue in 2030 | USD 379.8 million |
Growth rate | 9.3% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.18% in 2023. Horizon Databook has segmented the Australia blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
As part this effort, the government has allocated significant funding to support the development of new diagnostic tests & therapies for blood cancers, including leukemia, lymphoma, and myeloma. The initiative brings together leading research institutions, hospitals, and biotech companies to drive innovation & collaboration in the field.
Recently, in November 2023, The Leukemia Foundation launched an industry-first health service, "My Care Connect", to support Australians living with blood cancer. The online platform connects patients with a dedicated care coordinator who provides personalized support, guidance, and advocacy throughout their treatment journey.
This comprehensive service addresses the complex needs of blood cancer patients, including emotional, practical, and medical concerns. My Care Connect became first service of its kind in Australia and aimed to improve patient outcomes as well as quality of life for those affected by blood cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Australia blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account